At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Mar 10, 2026 at 08:00 ET
ImageneBio reported its Q4 and full-year 2025 financial results, highlighting a strong cash position of $135.3 million post-merger and ongoing Phase 2b ADAPTIVE trial for IMG-007 in atopic dermatitis. While R&D spending decreased slightly, G&A expenses more than doubled due to merger-related and personnel costs, leading to a wider net loss. No revenue or earnings guidance was provided, and the company remains in clinical development with no near-term commercial catalysts.
- Ended 2025 with $135.3 million in cash, up from $12.1 million in 2024, due to a reverse merger and $75 million private placement.
- R&D expenses decreased to $3.3M in Q4 2025 from $3.8M in Q4 2024.
- G&A expenses rose to $5.2M in Q4 2025 from $2.4M in Q4 2024, driven by merger costs and stock-based compensation.
- Net loss widened to $6.9M in Q4 2025 from $4.8M in Q4 2024.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access